Neurotech International Stock Current Valuation
| NTI Stock | 0.05 0 2.08% |
Valuation analysis of Neurotech International helps investors to measure Neurotech International's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At this time, Neurotech International's Cash And Short Term Investments are comparatively stable compared to the past year. Cash And Equivalents is likely to gain to about 5.8 M in 2025, despite the fact that Total Cashflows From Investing Activities is likely to grow to (1.1 M). Fundamental drivers impacting Neurotech International's valuation include:
Price Book 4.204 | Enterprise Value 38.4 M | Enterprise Value Ebitda (6.74) | Price Sales 15.7433 | Enterprise Value Revenue 19.6 K |
Overvalued
Today
Please note that Neurotech International's price fluctuation is out of control at this time. Calculation of the real value of Neurotech International is based on 3 months time horizon. Increasing Neurotech International's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Neurotech International's intrinsic value may or may not be the same as its current market price of 0.05, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.047 | Real 0.0452 | Hype 0.05 | Naive 0.0416 |
The intrinsic value of Neurotech International's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neurotech International's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neurotech International helps investors to forecast how Neurotech stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurotech International more accurately as focusing exclusively on Neurotech International's fundamentals will not take into account other important factors: Neurotech International Company Current Valuation Analysis
Neurotech International's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Neurotech International Current Valuation | 38.4 M |
Most of Neurotech International's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neurotech International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Neurotech International has a Current Valuation of 38.4 M. This is much higher than that of the Health Care Equipment & Supplies sector and significantly higher than that of the Health Care industry. The current valuation for all Australia stocks is notably lower than that of the firm.
Neurotech Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neurotech International's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neurotech International could also be used in its relative valuation, which is a method of valuing Neurotech International by comparing valuation metrics of similar companies.Neurotech International is currently under evaluation in current valuation category among its peers.
Neurotech Fundamentals
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.37 | ||||
| Profit Margin | (1.60) % | ||||
| Operating Margin | 135.32 % | ||||
| Current Valuation | 38.4 M | ||||
| Shares Outstanding | 1.04 B | ||||
| Shares Owned By Insiders | 32.54 % | ||||
| Shares Owned By Institutions | 2.22 % | ||||
| Price To Book | 4.20 X | ||||
| Price To Sales | 15.74 X | ||||
| Revenue | 1.96 K | ||||
| Gross Profit | 3.17 M | ||||
| EBITDA | (8.24 M) | ||||
| Net Income | (5.07 M) | ||||
| Total Debt | 314.7 K | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (4.6 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Target Price | 0.6 | ||||
| Beta | 1.48 | ||||
| Market Capitalization | 50.02 M | ||||
| Total Asset | 12.21 M | ||||
| Retained Earnings | (41.56 M) | ||||
| Working Capital | 11.9 M | ||||
| Net Asset | 12.21 M |
About Neurotech International Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neurotech International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurotech International using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurotech International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Neurotech Stock Analysis
When running Neurotech International's price analysis, check to measure Neurotech International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurotech International is operating at the current time. Most of Neurotech International's value examination focuses on studying past and present price action to predict the probability of Neurotech International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurotech International's price. Additionally, you may evaluate how the addition of Neurotech International to your portfolios can decrease your overall portfolio volatility.